We are live on
!
Find out more
RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.7B
1-Year Est. Return
93.03%
This Fund
S&P 500
This Quarter
Est. Return
+4.87%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.7B
AUM Growth
-$252M
(-13%)
Cap. Flow
-$160M
Cap. Flow
% of AUM
-9.43%
Top 10 Holdings %
Top 10 Hldgs %
40.6%
Holding
107
New
9
Increased
39
Reduced
24
Closed
6
Top Buys
| 1 |
MMED
MiniMed Group Inc
MMED
|
+$17.4M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
+$15M |
| 3 |
Boston Scientific
BSX
|
+$9.3M |
| 4 |
HTFL
Heartflow Inc
HTFL
|
+$8M |
| 5 |
PTC Therapeutics
PTCT
|
+$7.08M |
Top Sells
| 1 |
EXAS
Exact Sciences
EXAS
|
+$61.1M |
| 2 |
CDTX
Cidara Therapeutics
CDTX
|
+$45.3M |
| 3 |
FOLD
Amicus Therapeutics
FOLD
|
+$27.4M |
| 4 |
State Street SPDR S&P Biotech ETF
XBI
|
+$24M |
| 5 |
Travere Therapeutics
TVTX
|
+$21.9M |
Sector Composition
| 1 | Healthcare | 99.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Vera Therapeutics
VERA
$3.1B
| $20.3M | 1.19% |
503,585
-64,994
| -11% | -$2.8M |
|
27
Neurocrine Biosciences
NBIX
$17.3B
| $19.8M | 1.17% |
150,450
+24,950
| +20% | +$3.31M |
|
|
ACLX
28
DELISTED
Arcellx
ACLX
| $19.5M | 1.15% |
169,859
| – | – |
|
29
NewAmsterdam Pharma
NAMS
$3.89B
| $18.8M | 1.11% |
588,794
+31,600
| +6% | +$1.03M |
|
30
Pharvaris
PHVS
$2.41B
| $18.2M | 1.07% |
645,533
+22,131
| +4% | +$591K |
|
31
Erasca
ERAS
$6.06B
| $17.9M | 1.05% |
1,103,469
+151,759
| +16% | +$1.79M |
|
32
Dyne Therapeutics
DYN
$3.93B
| $17.6M | 1.04% |
972,198
+59,243
| +6% | +$1.02M |
|
33
Compass Therapeutics
CMPX
$394M
| $17.5M | 1.03% |
3,305,308
-621,894
| -16% | -$3.59M |
|
34
Aclaris Therapeutics
ACRS
$758M
| $16.8M | 0.99% |
4,472,650
+18,909
| +0.4% | +$63.8K |
|
35
Tarsus Pharmaceuticals
TARS
$2.45B
| $15.8M | 0.93% |
225,179
-35,165
| -14% | -$2.46M |
|
|
MMED
36
MiniMed Group Inc
MMED
$4.22B
| $15.7M | 0.93% |
+1,055,000
| New | +$17.4M |
|
37
Zai Lab
ZLAB
$2.18B
| $15.3M | 0.9% |
814,707
+3,161
| +0.4% | +$58.6K |
|
38
UnitedHealth
UNH
$386B
| $14.3M | 0.85% |
53,000
+12,200
| +30% | +$3.63M |
|
|
CNTA
39
DELISTED
Centessa Pharmaceuticals
CNTA
| $14M | 0.82% |
351,828
+27,813
| +9% | +$711K |
|
|
HTFL
40
Heartflow Inc
HTFL
$2.2B
| $13.9M | 0.82% |
572,500
+294,800
| +106% | +$8M |
|
41
Ardelyx
ARDX
$1.27B
| $13.8M | 0.81% |
2,299,473
| – | – |
|
42
Summit Therapeutics
SMMT
$12B
| $13.5M | 0.79% |
710,000
| – | – |
|
43
Azenta
AZTA
$1.17B
| $12M | 0.71% |
569,100
| – | – |
|
44
Mineralys Therapeutics
MLYS
$2.4B
| $11.9M | 0.7% |
439,751
+12,155
| +3% | +$356K |
|
45
Danaher
DHR
$141B
| $11.7M | 0.69% |
61,500
| – | – |
|
|
46
PTC Therapeutics
PTCT
$6.48B
| $11M | 0.65% |
161,798
+99,919
| +161% | +$7.08M |
|
|
CAI
47
Caris Life Sciences
CAI
$4.79B
| $10.1M | 0.59% |
563,000
-124,500
| -18% | -$2.72M |
|
|
ZBIO
48
Zenas BioPharma
ZBIO
$1.82B
| $9.82M | 0.58% |
502,077
| – | – |
|
|
BCAX
49
Bicara Therapeutics
BCAX
$1.85B
| $9.73M | 0.57% |
489,095
+60,000
| +14% | +$1.03M |
|
50
BridgeBio Pharma
BBIO
$16.5B
| $9.52M | 0.56% |
128,250
+24,750
| +24% | +$1.79M |
|
Similar funds
AAM
SGI
WAS
SI
PP
SWM
AAA
FDP